At Anthropic’s $81 Billion Nasdaq Debut, Dario Amodei Spoke About His Father

Last Updated:
Before the opening bell in New York on November 19, the co-founder of Claude recalled a medical breakthrough that came too late for his family. In doing so, he gave the public a way to judge what Anthropic does with its billions
On Thursday, shortly before Anthropic rang the Nasdaq opening bell, Dario Amodei brought up his father. He told the audience in New York about the treatment that came too late and why he believed artificial intelligence could help scientists develop the next one sooner
On Thursday, shortly before Anthropic rang the Nasdaq opening bell, Dario Amodei brought up his father. He told the audience in New York about the treatment that came too late and why he believed artificial intelligence could help scientists develop the next one sooner Credits: Getty

A few years after Riccardo Amodei died, his son says, the chances of curing the disease that killed him rose to roughly 95 per cent. On Thursday, shortly before Anthropic rang the Nasdaq opening bell, Dario Amodei brought up his father. According to The Guardian’s live account of the ceremony, he told the audience in New York about the treatment that came too late and why he believed artificial intelligence could help scientists develop the next one sooner.

Sign up for Open Magazine's ad-free experience
Enjoy uninterrupted access to premium content and insights.

Wall Street had its own figures to consider. Anthropic had priced 980 million shares at $83 apiece, above the $70 to $78 range it had given investors. The offering was worth $81.34 billion, of which about $79.38 billion was due to the company before fees. The maker of Claude came to Nasdaq with a valuation of roughly $1.5 trillion.

open magazine cover
Open Magazine Latest Edition is Out Now!

The Wealth Issue 2026

06 Nov 2026 - Vol 05 | Issue 45

Portraits of Dreamers and Doers under 35

Read Now The Wealth Issue 2026

The number I’d put alongside those billions is three or four years. That was Dario’s own estimate, in an earlier interview with Alex Kantrowitz for the Big Technology Podcast, of how little time had separated his father’s death from a sharp improvement in the cure rate. For a scientist looking back on a career, three or four years might sound like remarkably quick progress. A family can lose someone in that gap. By bringing his father into the IPO speech, Amodei has invited a question that shareholders and patients can both ask. How much of that time can Anthropic help a scientist save?

The two patients in Dario Amodei’s story

Riccardo was a leatherworker who grew up near the Italian island of Elba, according to Business Insider. He was ill for a long time and died in 2006, Dario told Kantrowitz. His illness helped draw his son to biology. As Dario described it, the deeper he went into the field, the more he wondered whether a human mind could make sense of all the biological processes involved in a disease. That question helped draw him to AI.

There was a second patient in the family. In his essay We Must Pace the Frontier, Dario wrote that “I myself survived an early-stage cancer that would not have been treatable even fifty years ago.” It is a detail worth reading alongside his Nasdaq remarks. The same man who knows what it is to lose a parent just before medicine catches up also knows what it is to walk out alive because someone else’s research reached him in time.

What would count as time saved?

Daniela Amodei, Anthropic’s president and Dario’s sister, had spoken a few minutes before him. “Plenty of technology is built to take up your time, we want Claude to give it back to you,” she said, according to MarketWatch’s coverage of the ceremony. She offered a decision customers could already judge: Anthropic had kept advertising off Claude. Then her brother took the same idea into territory where the company has considerably more to prove.

Plenty of technology is built to take up your time, we want Claude to give it back to you
Daniela Amodei, Anthropic’s president and Dario’s sister

There are already people in a position to tell us how that effort is going. In October, Anthropic identified 20 scientific foundations, institutions and research groups it had partnered with through its AI for Science programme, which gives researchers free credits to use Claude. I’d like to hear from one of those researchers a year from now. Which experiment did the lab run sooner? How much time did it recover once the scientists had checked Claude’s work? Did that change a decision about a treatment worth pursuing?

At $83 a share, investors gave a precise answer to what they would pay for Anthropic. Dario Amodei left them with a harder piece of arithmetic. Somewhere, a family is living through the years his father ran out of. How many of those years can Claude give back?